Alpha Cognition Inc., (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO).
“Henry brings to the Company over 20 years of experience in corporate accounting and finance, with a strong business background in the life science industry and we believe this an important addition to the Company as we prepare for commercialization,” said Michael McFadden, CEO of the Company.
Prior to joining Alpha Cognition, Mr. Du was Sr. Vice President of Accounting and Administration at Amplify Surgical, a medical device company focused on developing innovative endoscopic surgical techniques and spinal implant technologies, where he led the finance and accounting functions, as well as administrative roles including HR, payroll, compliance, corporate legal, and investor relations. During his tenure there, he was instrumental in helping the company achieve consistent positive EBITDA and profitability, along with doubling average daily operating liquidity. Mr. Du was also VP of Finance and Senior Corporate Controller at HUYABIO International, a leader in globalizing Chinese pharmaceutical innovation, where he established the commercial accounting policy for the company’s product launch in Japan. Prior to HUYABIO, Mr. Du served in leadership roles at Eledon Pharmaceuticals (formerly Novus Therapeutics), a publicly traded clinical-stage biopharmaceutical company, United Auto Credit, and at Avanir Pharmaceuticals.
“I am excited to join Alpha Cognition at such a critical juncture,” said Henry Du. “The opportunity to contribute to a company that is not only on the cusp of a major product launch but is also dedicated to delivering life-changing treatments is incredibly compelling. I look forward to helping steer the financial strategy for continued success.”
For similar news, please refer
KBI Biopharma appoints Jean-Baptiste Agnus as Chief Business Officer
Hansa Biopharma welcomes Dr. Hitto Kaufmann as Chief Scientific Officer
